2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2025-11-1-0-53684Pharmacology<strong>Spectrum of anti-inflammatory, anti-infectious and anti-tumor activity of quinazoline and quinazolinone derivatives (review)</strong><br /> &nbsp;<strong>Spectrum of anti-inflammatory, anti-infectious and anti-tumor activity of quinazoline and quinazolinone derivatives (review)</strong><br /> &nbsp;ManvelyanMikael M.ManvelyanMikael M.mik.manvelyan@mail.ruManvelyanEleonora A.ManvelyanEleonora A.manveljan@rambler.ruBaturinVladimir A.BaturinVladimir A.stav.clin.pharm@mail.ruBunyatyanNatalia D.BunyatyanNatalia D.ndbun@mail.ru202511100

Background: A new class of medicinal compounds &ndash; derivatives of quinazoline and quinazolinone have been actively studied in recent years, on their basis drugs with polyvalent influence are created. The concept of multifunctional agents is being actively developed and has yielded encouraging results. In clinical practice, many highly active quinazoline and quinazolinone derivatives extracted from plants, bacteria, fungi are used. Quinazoline and quinazolinone cycles are unique pharmacophore groups contributing to the structure and activity of drugs widely used in medical practice. The aim of the study: Analysis of current literature data on studies of anti-inflammatory, anti-infectious, anti-tumor activity of quinazoline and quinazolinone derivatives. Materials and methods: A theoretical analysis of the published results of studying the pharmacological effects of quinazoline and quinazolinone derivatives with various substituents was carried out, the search was carried out according to works in the public domain in the PubMed, Elibrary, Scopus databases. When analyzing the literature data, special attention was paid to systematic reviews and meta-analyses of the results of scientific research. Results: The most common derivatives are 4 (3H) -quinazolinone. For quinazoline and quinazolinone derivatives, anti-inflammatory effects in paw edema, ischemic brain damage, neuroinflammation, rheumatoid arthritis, osteoarthritis, osteoarthrosis are indicated. The anti-infectious effect of the compounds on the causative agents of diseases is described: viral (Varicella Zoster Viruses, Cytomegalovirus, HIV, SARS-CoV-2, MERS-CoV, Chikungunya), bacterial (gram-negative and gram-positive clinically pathogenic strains), protozoal (N. fowleri, B. mandrillaris, Acanthamoeba castellanii, P. falciparum, Trypanosoma brucei, Leishmania infantum), fungal. Antitumor derivatives shown in cancer of various organs and systems have been established. For many derivatives, the mechanisms of virucidal, antimicrobial, antiprotozoal, fungicidal, antiblastoma actions have been investigated. Conclusion: The interest shown in quinazoline and quinazolinone derivatives with anti-infectious, anti-inflammatory, cytostatic effects is colossal and continues to grow. The study of new derivatives of this series as compounds with polypharmacological activity is relevant, can contribute to increasing the effectiveness of drug treatment in patients with inflammatory, infectious and tumor diseases, will reduce the number of prescribed drugs, the frequency and severity of their side effects

Background: A new class of medicinal compounds &ndash; derivatives of quinazoline and quinazolinone have been actively studied in recent years, on their basis drugs with polyvalent influence are created. The concept of multifunctional agents is being actively developed and has yielded encouraging results. In clinical practice, many highly active quinazoline and quinazolinone derivatives extracted from plants, bacteria, fungi are used. Quinazoline and quinazolinone cycles are unique pharmacophore groups contributing to the structure and activity of drugs widely used in medical practice. The aim of the study: Analysis of current literature data on studies of anti-inflammatory, anti-infectious, anti-tumor activity of quinazoline and quinazolinone derivatives. Materials and methods: A theoretical analysis of the published results of studying the pharmacological effects of quinazoline and quinazolinone derivatives with various substituents was carried out, the search was carried out according to works in the public domain in the PubMed, Elibrary, Scopus databases. When analyzing the literature data, special attention was paid to systematic reviews and meta-analyses of the results of scientific research. Results: The most common derivatives are 4 (3H) -quinazolinone. For quinazoline and quinazolinone derivatives, anti-inflammatory effects in paw edema, ischemic brain damage, neuroinflammation, rheumatoid arthritis, osteoarthritis, osteoarthrosis are indicated. The anti-infectious effect of the compounds on the causative agents of diseases is described: viral (Varicella Zoster Viruses, Cytomegalovirus, HIV, SARS-CoV-2, MERS-CoV, Chikungunya), bacterial (gram-negative and gram-positive clinically pathogenic strains), protozoal (N. fowleri, B. mandrillaris, Acanthamoeba castellanii, P. falciparum, Trypanosoma brucei, Leishmania infantum), fungal. Antitumor derivatives shown in cancer of various organs and systems have been established. For many derivatives, the mechanisms of virucidal, antimicrobial, antiprotozoal, fungicidal, antiblastoma actions have been investigated. Conclusion: The interest shown in quinazoline and quinazolinone derivatives with anti-infectious, anti-inflammatory, cytostatic effects is colossal and continues to grow. The study of new derivatives of this series as compounds with polypharmacological activity is relevant, can contribute to increasing the effectiveness of drug treatment in patients with inflammatory, infectious and tumor diseases, will reduce the number of prescribed drugs, the frequency and severity of their side effects

quinazolinesquinazolinonesanti-inflammatoryanti-infective and antitumor activityquinazolinesquinazolinonesanti-inflammatoryanti-infective and antitumor activityСписок литературыMass EB, Duarte GV, Russowsky D. The Quinazoline-Chalcone and Quinazolinone-Chalcone Hybrids: A Promising Combination for Biological Activity. Mini-Reviews in Medicinal Chemistry. 2021;21(2):186-203. DOI: https://doi.org/10.2174/1389557520666200730160325Zayed MF. Medicinal Chemistry of Quinazolines as Analgesic and Anti-Inflammatory Agents. ChemEngineering. 2022;6(6):94. DOI: https://doi.org/10.3390/chemengineering6060094Аbuelizz HA, Al-Salahi R. Significant pharmacological activities of benzoquinazolines scaffold. Pharmacological Reports. 2023;75(2):223-235. DOI: https://doi.org/10.1007/s43440-023-00453-9Alagarsamy V, Chitra K, Saravanan G, et al. An overview of quinazolines: Pharmacological significance and recent developments. European Journal of Medicinal Chemistry. 2018;151:628-685. DOI: https://doi.org/10.1016/j.ejmech.2018.03.076Moussa G, Alaaeddine R, Alaeddine LM, et al. Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study. European Journal of Medicinal Chemistry. 2018;144:635-650. DOI: https://doi.org/10.1016/j.ejmech.2017.12.065Gill J, Sharma A. Prospects of halofuginone as an antiprotozoal drug scaffold. Drug Discovery Today. 2022;27(9):2586-2592. DOI: https://doi.org/10.1016/j.drudis.2022.05.020Kuchinsky MP, Savchuk TM, Kuchinskaya GM, et al. Study of the toxicity of an antiprotozoic veterinary preparation based on a derivative of hinazolinone. Epizootology Immunobiology Pharmacology Sanitation. 2022;1:68-74. Russian. DOI: https://doi.org/10.47612/2224-168X-2022-1-68-74Tye MA, Payne NC, Johansson C, et al. Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance. Nature Communications. 2022;13(1):4976. DOI: https://doi.org/10.1038/s41467-022-32630-4Pitera AP, Szaruga M, Peak-Chew SY, et al. Cellular responses to halofuginone reveal a vulnerability of the GCN2 branch of the integrated stress response. EMBO Journal. 2022;41(11):e109985. DOI: https://doi.org/10.15252/embj.2021109985Lv T, Huang J, Wu M, et al. Halofuginone enhances the anti-tumor effect of ALA-PDT by suppressing NRF2 signaling in cSCC. Photodiagnosis and Photodynamic Therapy. 2022;37:102572. DOI: https://doi.org/10.1016/j.pdpdt.2021.102572Li X, Ge J, Zheng Q, et al. Evodiamine and rutaecarpine from Tetradium ruticarpum in the treatment of liver diseases. Phytomedicine. 2020;68:153180. DOI: https://doi.org/10.1016/j.phymed.2020.153180Singhai A, Patil UK. Amelioration of oxidative and inflammatory changes by Peganum harmala seeds in experimental arthritis. Clinical Phytoscience. 2021;7:13. DOI: https://doi.org/10.1186/s40816-020-00243-3Fahmy SA, Issa MY, Saleh BM, et al. Peganum harmala Alkaloids Self-Assembled Supramolecular Nanocapsules with Enhanced Antioxidant and Cytotoxic Activities. ACS Omega. 2021;6(18):11954-11963. DOI: https://doi.org/10.1021/acsomega.1c00455Fan M, Yao L. The Synthesis, Structural Modification and Mode of Anticancer Action of Evodiamine: A Review. Recent Patents on Anti-Cancer Drug Discovery. 2022;17(3):284-296. DOI: https://doi.org/10.2174/1574892817666211221165739Manvelyan ЕА, Manvelyan MМ, Codоnidi IP, et al. Аnalgesic activity of new derivatives of quinazolinone-4. Medical News of North Caucasus. 2017;12(3):307-311. DOI: https://doi.org/10.14300/mnnc.2017.12089Manvelyan MM, Manvelyan EA, Baturin VA, et al. Anticataleptic activity of 2-substituted derivatives of 3(H)-quinazolin-4-one. Medical News of North Caucasus. 2021;16(2):191-193. DOI: https://doi.org/10.14300/mnnc.2017.12089Shaaban MА, Kamal AМ, Faggal SI, et al. Design, synthesis, and biological evaluation of new pyrazoloquinazoline derivatives as dual COX-2/5-LOX inhibitors. Archiv der Pharmazie. 2020;353(11):2000027. DOI: https://doi.org/10.1002/ardp.202000027Kodonidi IP, Larski MV, Kodonidi MI, et al. Targeted synthesis of quinazoline-4(3H)-one derivatives and their acyclic precursors with given pharmacological properties. Moscow: Rusains; 2022. Russian.Abuelizz HA, Al-Salahi R. An overview of triazoloquinazolines: Pharmacological significance and recent developments. Bioorganic Chemistry. 2021;115:105263. DOI: https://doi.org/10.1016/j.bioorg.2021.105263Yu SJ, Wu KJ, Wang YS, et al. Protective Effect of CXCR4 Antagonist CX807 in a Rat Model of Hemorrhagic Stroke. International Journal of Molecular Sciences. 2020;21(19):7085. DOI: https://doi.org/10.3390/ijms21197085Hejazi L, Rezaee E, Tabatabai SA. Quinazoline-4(3H)-one derivatives as novel and potent inhibitors of soluble epoxide hydrolase: Design, synthesis and biological evaluation. Bioorganic Chemistry. 2020;99:103736. DOI: https://doi.org/10.1016/j.bioorg.2020.103736Turanlı S, Erg&uuml;l AG, Jordan PM, et al. Quinazoline-4(3H)-one-7-carboxamide Derivatives as Human Soluble Epoxide Hydrolase Inhibitors with Developable 5-Lipoxygenase Activating Protein Inhibition. ACS Omega. 2022;7(41):36354-36365. DOI: https://doi.org/10.1021/acsomega.2c04039Poladashvili RO. Study of the anti-inflammatory activity of quinazolinone-4 derivatives and their acyclic forms. Trends in the development of science and education. 2020;68(2):72-73. Russian. DOI: https://doi.org/10.18411/lj-12-2020-71Manne MR, Panicker RR, Ramakrishnan K, et al. Synthesis and Biological Evaluation of a Series of Quinoline‐Based Quinazolinones and Carbamic Anhydride Derivatives. ChemistrySelect. 2023;8(3):e202204508 DOI: https://doi.org/10.1002/slct.202204508Grabkowska-Drużyc M, Andrei G, Schols D, et al. Isoxazolidine Conjugates of N3-Substituted 6-Bromoquinazolinones&mdash;Synthesis, Anti-Varizella-Zoster Virus, and Anti-Cytomegalovirus Activity. Molecules. 2018;23:1889. DOI: https://doi.org/10.3390/molecules23081889Badolato M, Aiello F, Neamati N. 2,3-Dihydroquinazolin-4(1H)-one as a privileged scaffold in drug design. RSC Advances. 2018;8(37):20894-20921. DOI: https://doi.org/10.1039/c8ra02827cAlemi M, Kamali F, Vahabpour Roudsari R, et al. Synthesis, Biological Evaluation, and Molecular Modeling Studies of New 8-methyl-4-oxo-1,4-dihydroquinoline-3-carbohydrazides as Potential Anti-HIV Agents. Iranian Journal of Pharmaceutical Research. 2022;21(1):e123962. DOI: https://doi.org/10.5812/ijpr-123962Lee JY, Shin YS, Jeon S, et al. Synthesis and biological evaluation of 2-benzylaminoquinazolin-4(3H)-one derivatives as a potential treatment for SARS-CoV-2. Bulletin of the Korean Chemical Society. 2022;43(3):412-416. DOI: https://doi.org/10.1002/bkcs.12470Shin YS, Lee JY, Jeon S, et al. Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: Improved Synthesis and Pharmacokinetic Properties. Pharmaceuticals. 2022;15(7):831. DOI: https://doi.org/10.3390/ph15070831Chiryapkin AS, Kodonidi IP, Pozdnyakov MD. Anticoronavirus activity of azomethines, thienopyrimidines and derivatives of 6,7-dimethoxyquinazoline-4(3H)-one. Alley of Science. 2022;1(10):245-248. Russian.Krysantieva AI, Voronina JK, Safin DA. A Novel Ambroxol-Derived Tetrahydroquinazoline with a Potency against SARS-CoV-2 Proteins. International Journal of Molecular Sciences. 2023;24(5):4660. DOI: https://doi.org/10.3390/ijms24054660Hwu JR, Roy A, Tsay SC, et al. Computer-Aided Design and Synthesis of (Functionalized quinazoline)-(&alpha;-substituted coumarin)-arylsulfonate Conjugates against Chikungunya Virus. International Journal of Molecular Sciences. 2022;23(14):7646. DOI: https://doi.org/10.3390/ijms23147646Abuelizz HA, El-Dib RA, Marzouk M, et al. In vitro evaluation of new 2-phenoxy-benzo[g][1,2,4]triazolo[1,5-a]quinazoline derivatives as antimicrobial agents. Microbial Pathogenesis. 2018;117:60-67. DOI: https://doi.org/10.1016/j.micpath.2018.02.018Osman EO, Emam SH, Sonousi A, et al. Design, synthesis, anticancer, and antibacterial evaluation of some quinazolinone-based derivatives as DHFR inhibitors. Drug Development Research. 2023;84(5):888-906. DOI: https://doi.org/10.1002/ddr.22060Rakesh KP, Suhas R, Shivakumar, et al. Еffect of low charge and high hydrophobicity on antimicrobial activity of the quinazolinone-peptide conjugates. Russian Journal of Bioorganic Chemistry. 2018;44(2):158-164. DOI: https://doi.org/10.1134/S1068162018020036Malasala S, Ahmad MN, Akunuri R, et al. Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis. European Journal of Medicinal Chemistry. 2021;212:112996. DOI: https://doi.org/10.1016/j.ejmech.2020.112996Gatadi S, Lakshmi TV, Nanduri S. 4(3H)-Quinazolinone derivatives: Promising antibacterial drug leads. European Journal of Medicinal Chemistry. 2019;170:157-172. DOI: https://doi.org/10.1016/j.ejmech.2019.03.018Algohary AM, Hassan AMA, Alzahrani AY, et al. Microwave‐ultrasonic assisted synthesis, and characterization of novel 3&prime;‐(amino, hydrazino and hydrazide)‐6&prime;‐bromo‐spiro(isobenzofuran‐1,2&prime;‐quinazoline)‐3,4&prime;‐dione derivatives as antimicrobial agents. Journal of Heterocyclic Chemistry. 2023;60(6):1014-1026. DOI: https://doi.org/10.1002/jhet.4647Almeida MC, Szemer&eacute;di N, Dur&atilde;es F, et al. Effect of Indole-Containing Pyrazino[2,1-b]quinazoline-3,6-diones in the Virulence of Resistant Bacteria. Antibiotics. 2023;12(5):922. DOI: https://doi.org/10.3390/antibiotics12050922Starikova AA, Samotrueva MA, Zolotareva NV, et al. Study of the relationship between the antimicrobial and hypoglycaemic activities of new quinazolinones by mathematical modelling. Caspian Journal of Medicine and Pharmacy. 2023;4(1):63-70. Russian. DOI: https://doi.org/10.29039/2712-8164-2023-1-63-70Samotrueva MA, Starikova AA, Bashkina O, et al. Biochemical basis of the antimicrobial activity of quinazolinone derivatives in the light of insights into the features of the chemical structure and ways of binding to target molecules. A review. Reports of the Russian Academy of Sciences. Chemistry, materials sciences. 2023;510(1):3-27. Russian. DOI: https://doi.org/10.31857/S2686953522600672Mungroo MR, Shahbaz MS, Anwar A, et al. Aryl Quinazolinone Derivatives as Novel Therapeutic Agents against Brain-Eating Amoebae. ACS Chemical Neuroscience. 2020;11(16):2438-2449. DOI: https://doi.org/10.1021/acschemneuro.9b00596Shahbaz MS, Anwar A, Saad SM, et al. Antiamoebic activity of 3-aryl-6,7-dimethoxyquinazolin-4(3H)-one library against Acanthamoeba castellanii. Parasitology Research. 2020;119(7):2327-2335. DOI: https://doi.org/10.1007/s00436-020-06710-7Ansari A, Seth A, Dutta M, et al. Discovery, SAR and mechanistic studies of quinazolinone-based acetamide derivatives in experimental visceral leishmaniasis. European Journal of Medicinal Chemistry. 2023;257:115524. DOI: https://doi.org/10.1016/j.ejmech.2023.115524Amrane D, Gellis A, Hutter S, et al. Synthesis and Antiplasmodial Evaluation of 4-Carboxamido- and 4-Alkoxy-2-Trichloromethyl Quinazolines. Molecules. 2020;25(17):3929. DOI: https://doi.org/10.3390/molecules25173929Long S, Duarte D, Carvalho C, et al. Indole-Containing Pyrazino[2,1-b]quinazoline-3,6-diones Active against Plasmodium and Trypanosomatids. ACS Medicinal Chemistry Letters. 2022;13(2):225-235. DOI: https://doi.org/10.1021/acsmedchemlett.1c00589Bansal R, Malhotra A. Therapeutic progression of quinazolines as targeted chemotherapeutic agents. European Journal of Medicinal Chemistry. 2021;211:113016. DOI: https://doi.org/ 10.1016/j.ejmech.2020.113016Das R, Mehta DK, Dhanawat M. Bestowal of Quinazoline Scaffold in Anticancer Drug Discovery. Anti-Cancer Agents in Medicinal Chemistry. 2021;21(11):1350-1368. DOI: https://doi.org/ 10.2174/1871520620666200627205321Kovalev IS, Zyryanov GV, Santra S, et al. Folic Acid Antimetabolites (Antifolates): A Brief Review on Synthetic Strategies and Application Opportunities. Molecules. 2022;27(19):6229. DOI: https://doi.org/10.3390/molecules27196229Șandor A, Ionuț I, Marc G, et al. Structure&ndash;Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017&ndash;Present). Pharmaceuticals. 2023;16(4):534. DOI: https://doi.org/10.3390/ph16040534Wang H, Zeng C, Li X, et al. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer. Future Oncology. 2019;15(2):181-191. DOI: https://doi.org/10.2217/fon-2018-0692Dou D, Wang J, Qiao Y, et al. Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors. European Journal of Medicinal Chemistry. 2022;244:114856. DOI: https://doi.org/10.1016/j.ejmech.2022.114856Chen C-T, Chang Y-C, Tseng P-X, et al. Asymmetric Synthesis of Trifluoroethyl-Based, Chiral 3-Benzyloxy-1- and -2-Phenyl-quinazolinones of Biomedicinal Interest by Radical Type Cross-Coupling to Olefins. International Journal of Molecular Sciences. 2023;24(1):513. DOI: https://doi.org/10.3390/ijms24010513El-Gazzar YI, Ghaiad HR, El Kerdawy AM, et al. New quinazolinone‐based derivatives as DHFR/EGFR‐TK inhibitors: Synthesis, molecular modeling simulations, and anticancer activity. Archiv der Pharmazie. 2023;356(1)е2200417. DOI: https://doi.org/10.1002/ardp.202200417Li Y, Xiao J, Zhang Q, et al. The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton. Bioorganic and Medicinal Chemistry. 2019;27(3):568-577. DOI: https://doi.org/10.1016/j.bmc.2018.12.032Cuartas V, Arag&oacute;n-Muriel A, Liscano Y, et al. Anticancer activity of pyrimidodiazepines based on 2-chloro-4-anilinoquinazoline: synthesis, DNA binding and molecular docking. RSC Advances. 2021;11(38):23310-23329. DOI: https://doi.org/10.1039/d1ra03509fKwiatkowski J, Kuliszkiewicz-Janus M, Rymer W, et al. Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function. Pharmacology. 2021;106(5-6):316-322. DOI: https://doi.org/10.1159/000513377Osipov VN, Balaev AN, Gromyko AV., et al. 3-Hydroxyquinazolin-4(3H)-one derivatives as histone deacetylase inhibitors and methods for their preparation. Patent of the Russian Federation RU 2740503 C1, 01/14/2021. Russian.Anjibo PR, Keroll OAJ, Pilatt INC, et al. Quinazolinone derivatives applicable as FGFR kinase modulators. Patent of the Russian Federation RU 2701517 C2. 27.09.2019. Russian.Dorsch D, Buchstaller H-P. Quinazolinone derivatives as PARP inhibitors. Patent of the Russian Federation RU 2650107 C2. 09.04.2018. Russian.Li W-CH, Liao B. Quinazolinone derivative, method of its preparation, pharmaceutical composition and application. Patent of the Russian Federation RU 2730500C2. 24.08.2020. Russian.Zhang Y, Hou Q, Li X, et al. Enrichment of novel quinazoline derivatives with high antitumor activity in mitochondria tracked by its self-fluorescence. European Journal of Medicinal Chemistry. 2019;178:417-432. DOI: https://doi.org/10.1016/j.ejmech.2019.06.015King L, Christie D, Dare W, et al. Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedside. European Journal of Pharmacology. 2021;893:173831. DOI: https://doi.org/10.1016/j.ejphar.2020.173831Dahabiyeh LA., Hudaib F, Hourani W, et al. Mass spectrometry-based metabolomics approach and in vitro assays revealed promising role of 2,3-dihydroquinazolin-4(1H)-one derivatives against colorectal cancer cell lines. European Journal of Pharmaceutical Sciences. 2023;182:106378. DOI: https://doi.org/10.1016/j.ejps.2023.106378Long S, Resende D, Kijjoa A, et al. Synthesis of new proteomimetic quinazolinone alkaloids and evaluation of their neuroprotective and antitumor effects. Molecules. 2019;24(3):534. DOI: https://doi.org/10.3390/molecules24030534Taayoshi F, Iraji A, Moazzam A, et al. Synthesis, molecular docking, and cytotoxicity of quinazolinone and dihydroquinazolinone derivatives as cytotoxic agents. BMC Chemistry. 2022;16(1):35. DOI: https://doi.org/10.1186/s13065-022-00825-xEl-Adl K, Ibrahim MK, Alesawy MSI, et al. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4&#39;,3&#39;-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies. Bioorganic and Medicinal Chemistry. 2021;30:115958. DOI: https://doi.org/10.1016/j.bmc.2020.115958Pedrood K, Taayoshi F, Moazzam A, et al. Design, synthesis, and cytotoxic evaluation of quinazoline derivatives bearing triazole-acetamides. Heliyon. 2023;9(2):e13528. DOI: https://doi.org/10.1016/j.heliyon.2023.e13528Xiu AY, Ding Q, Li Z, et al. Doxazosin Attenuates Liver Fibrosis by Inhibiting Autophagy in Hepatic Stellate Cells via Activation of the PI3K/Akt/mTOR Signaling Pathway. Drug Design, Development and Therapy. 2021;15:3643-3659. DOI: https://doi.org/10.2147/DDDT.S317701Pan ES, Pakhomova AV, Ermakova NN, et al. Age-related features of ketanserin effects on experimental liver cirrosis. Bulletin of Experimental Biology and Medicine. 2022;174(8):166-171. Russian. DOI: https://doi.org/10.47056/0365-9615-2022-174-8-166-171